Reyataz (Atazanavir)

The Basics

An Overview of Reyataz (Atazanavir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
FAQs About Reyataz (Atazanavir) From The Body's "Ask the Experts" Forums (Regularly Updated)
From The Body's "Ask the Experts" Forums
Atazanavir (Reyataz) (August 22, 2009)
To read PDF, click here
From AIDS InfoNet
Patient Information About Reyataz (Atazanavir) (PDF) (April 2009)
From Bristol-Myers Squibb Company
Reyataz (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Reyataz (Atazanavir) (September 28, 2008)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Reyataz (Atazanavir) Package Insert Revisions (January 16, 2008)
From U.S. Food and Drug Administration
Atazanavir (Reyataz) (August 15, 2006)
From AIDS Treatment Data Network
Labeling Changes for Atazanavir (Reyataz) (January 26, 2006)
To read PDF, click here
From U.S. Food and Drug Administration

News & Research

Boosted and Unboosted Atazanavir Maintain Viral Suppression Equally Well (July 23, 2009)
Unboosted atazanavir taken once-daily as part of a combination antiretroviral regimen can keep viral load undetectable in patients who discontinue ritonavir, researchers reported.
From aidsmap.com
Nevirapine Sports Better Lipid Profile Than Atazanavir, Study Suggests (July 20, 2009)
Patients taking nevirapine may have a lower risk of developing cardiovascular disease than those taking ritonavir-boosted atazanavir, according to a 569-patient study by European researchers. The study found that although nevirapine's efficacy was non-inferior to that of atazanavir, nevirapine appeared to have a more favorable lipid profile.
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Reyataz and Sustiva Co-Pay Benefit Program (April 16, 2009)
If you live in the U.S., you might be eligible for a benefits program created to help people who are already insured, but still need help to pay for Reyataz or Sustiva.
From Bristol-Myers Squibb Company
Warnings About Taking Reyataz With Sustiva, Viramune, Oral Contraceptives (August 21, 2008)
From U.S. Food and Drug Administration
Switch to Atazanavir Does Not Reduce Belly Fat (August 4, 2008)
From aidsmap.com
New Pediatric Dosing Recommendations for Reyataz Capsules, Patients Ages 6 to 18 Years Old (March 26, 2008)
To read PDF, click here
From U.S. Food and Drug Administration
Atazanavir Noninferior to Lopinavir in Treatment-Naive HIV-Infected People (February 6, 2008)
From The Body PRO
Reyataz Monotherapy Study Stopped (October 2007)
To read PDF, click here
In Project Inform Perspective, from Project Inform
ATAZIP: Switching Away From Lopinavir/Ritonavir (July 25, 2007)
Switching from lopinavir/ritonavir (Kaletra) to atazanavir (Reyataz)/ritonavir (Norvir) maintains virologic efficacy and leads to sustained improvements in lipid levels. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Bristol-Myers Squibb Receives FDA Approval for New Formulation of Antiretroviral Reyataz (October 24, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
New 300 mg Reyataz Capsule Approved (October 23, 2006)
From U.S. Food and Drug Administration
Increased I50L Prevalence Found After Unboosted Atazanavir Use in PI-Treatment-Experienced Patients (August 17, 2006)
In XVI International AIDS Conference
Switching From Lopinavir/Ritonavir to Unboosted Atazanavir May Yield Benefits, but Verdict Remains Uncertain (August 17, 2006)
In XVI International AIDS Conference
Acid-Reducing Agents Reduce Atazanavir Drug Levels but Not Lopinavir/Ritonavir Levels (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used (February 6, 2006)
However, boosting with atazanavir instead of ritonavir does appear feasible, this study finds.
In The 13th Conference on Retroviruses and Opportunistic Infections
Atazanavir, With or Without Ritonavir, Should Not Be Coadministered With Proton Pump Inhibitors (December 20, 2004)
From U.S. Food and Drug Administration
New Dosing Regimen for Ritonavir-Boosted Atazanavir in Treatment-Experienced Patients; Revisions Made to Packaging Insert (July 7, 2004)
From U.S. Food and Drug Administration
Atazanavir/Tenofovir Combo Should Be Boosted With Ritonavir (August 8, 2003)
From U.S. Food and Drug Administration